Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 3 years, the average EBITDA Per Share Growth Rate was 19.30% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was -8.80% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was -1.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Ultragenyx Pharmaceutical was 32.20% per year. The lowest was -90.10% per year. And the median was -14.65% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Ultragenyx Pharmaceutical 3-Year EBITDA Growth Rate Related Terms
MEX:RARE vs PGEN, PHVS, NKTR: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Ultragenyx Pharmaceutical's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ultragenyx Pharmaceutical 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ultragenyx Pharmaceutical's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Ultragenyx Pharmaceutical's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 19.30% mean?
Ultragenyx Pharmaceutical (MEX:RARE) has a 3-Year EBITDA Growth Rate of 19.30% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Ultragenyx Pharmaceutical and its competitors. According to the industry distribution chart, Ultragenyx Pharmaceutical ranks #504 out of 1127 companies in the Biotechnology industry, placing it in the top 44.7%.
Is Ultragenyx Pharmaceutical's 3-Year EBITDA Growth Rate too high?
Ultragenyx Pharmaceutical's current 3-Year EBITDA Growth Rate is 19.30%. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.90. Ultragenyx Pharmaceutical's value of 19.30% is 29.5% above this industry median. Based on the distribution chart, Ultragenyx Pharmaceutical ranks #504 out of 1127 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Ultragenyx Pharmaceutical has a GF Score™ of 59/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Ultragenyx Pharmaceutical's 3-Year EBITDA Growth Rate compare to PGEN and PHVS?
According to the Biotechnology industry distribution chart, Ultragenyx Pharmaceutical ranks #504 out of 1127 companies for 3-Year EBITDA Growth Rate. This puts Ultragenyx Pharmaceutical in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.90. Ultragenyx Pharmaceutical's value of 19.30% is 29.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.90, based on 1,127 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ultragenyx Pharmaceutical's current 3-Year EBITDA Growth Rate of 19.30% is 29.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Ultragenyx Pharmaceutical and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ultragenyx Pharmaceutical's current 3-Year EBITDA Growth Rate is 19.30%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ultragenyx Pharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, Ultragenyx Pharmaceutical (MEX:RARE) is currently considered Possible Value Trap. The stock's GF Value™ is MXN807.36, compared to a current price of MXN450.00 — trading 44.3% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 19.30% and 29.5% above the Biotechnology industry median of 14.90. Ultragenyx Pharmaceutical's overall GF Score™ is 59/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Ultragenyx Pharmaceutical (MEX:RARE), the current 3-Year EBITDA Growth Rate is 19.30% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ultragenyx Pharmaceutical (MEX:RARE) Overvalued in 2026?
Based on GuruFocus' analysis, Ultragenyx Pharmaceutical stock appears to be undervalued.
The current stock price of MXN450.00 is trading 44.3% below its estimated GF Value™ of MXN807.36.
GuruFocus considers Ultragenyx Pharmaceutical to be Possible Value Trap.
Key valuation signals for MEX:RARE:
3-Year EBITDA Growth Rate: 19.30%
GF Value™: MXN807.36 vs. price of MXN450.00 (44.3% below fair value)
Industry Position: 29.5% above the Biotechnology median (#504 of 1127)
No single metric tells the full story. See the MEX:RARE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.
59GF Score
Get the complete analysis for MEX:RARE
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:RARE has been successfully added to your 
